Immune checkpoint inhibitor retreatment in second-line treatment of esophageal cancer: A real-world study.

被引：0
|
作者：
Kang, Yixin
Zhang, Dianbao
Mi, Youjia
Niu, Xiedong
Kang, Yuan
Xie, Dongjie
Li, Wenyao
Zhang, Ce
Yang, Junqiang
Yao, Jun
机构：
[1] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[2] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Gastroenterol Oncol, Luoyang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16034
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence
    Cuker, Adam
    Buckley, Brian
    Mousseau, Marie-Catherine
    Barve, Aditya Anand
    Haenig, Jens
    Bussel, James B.
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2051 - 2058
  • [42] Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer
    Zhang, Shijia
    Pease, Daniel F.
    Kulkarni, Amit A.
    Kumar, Manoj
    Shanley, Ryan M.
    Xu, Beibei
    Joshi, Shilvi P.
    Patel, Manish R.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2021, 15
  • [43] Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence
    Adam Cuker
    Brian Buckley
    Marie-Catherine Mousseau
    Aditya Anand Barve
    Jens Haenig
    James B. Bussel
    Annals of Hematology, 2023, 102 : 2051 - 2058
  • [44] Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer
    Liepa, Astra M.
    Cui, Zhanglin Lin
    Beyrer, Julie K.
    Hadden, Elizabeth L.
    Chatterjee, Anindya
    FUTURE ONCOLOGY, 2023, 19 (18) : 1277 - 1291
  • [45] Regorafenib combined with transarterial chemoembolization and PD-1 antibody as a second-line therapy for hepatocellular carcinoma: A real-world study.
    Pan, Tao
    Huang, Mingsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16167 - E16167
  • [46] Second-line drug regimens in metastatic melanoma patients based on BRAF mutation status: A Canadian real-world retrospective study.
    Bremner, Samantha
    Lapierre, Marc
    Fraelic, Arushi
    Stewart, Dave
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy benefit in first-line metastatic urothelial carcinoma: A real-world study.
    Gupta, Shilpa
    Huang, Richard S. P.
    Stanke, Jennifer
    Hamdani, Omar
    Gjoerup, Ole
    Alexander, Brian Michael
    Levy, Mia Alyce
    Oxnard, Geoffrey R.
    Graf, Ryon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [48] Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
    Blomstrand, Hakon
    Batra, Atul
    Cheung, Winson Y.
    Elander, Nils Oskar
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (09): : 787 - 799
  • [49] Real-world characteristics and outcomes of patients with multiple myeloma receiving second-line treatment in England
    Moore, Sally
    Cornic, Laura
    Crossman-Barnes, Christina-Jane
    Jose, Sophie
    Khalaf, Zeyad
    Yong, Kwee
    Soutar, Megan
    Woods, Philip
    EJHAEM, 2025, 6 (01):
  • [50] FIRST AND SECOND LINE TREATMENT CHOICES FOR ENDOMETRIAL CANCER: ECHOS-A REAL-WORLD STUDY
    Abreu, G.
    Queiroz, J.
    Nogueira da Silva, T. L.
    Soares, C.
    Menezes, P.
    Carrizo, M.
    Scibona, P.
    Simonovich, V. A.
    Riggi, M. C.
    Saadi, J. J.
    Cravero, F.
    Jotimliansky, L.
    VALUE IN HEALTH, 2023, 26 (12) : S527 - S527
12345